Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genetic Aberration Paves the Way for New Treatment of Cancer Disease

Published: Friday, November 08, 2013
Last Updated: Friday, November 08, 2013
Bookmark and Share
Research was recently published in Scandinavian Journal of Gastroenterology.

Researchers from Faculty of Health and Medical Sciences, University of Copenhagen, have characterized a genetic aberration on a group of colorectal cancer patients.

The discovery gives hope for a new and efficient treatment of colorectal cancer, which is a frequent and often fatal disease.

12-15 years of development and millions of dollars are typically the costs, when companies develop a new anti-cancer drug.

Therefore all short cuts to a treatment are welcome. Researchers at Department of Veterinary Disease Biology, University of Copenhagen, recently discovered such a potential short cut.

“Our new research shows, that we might be able to introduce a treatment faster and cheaper than usual in the development of cancer treatment, and we estimate that it will be efficient in around 10 per cent of patients with colorectal cancer," says MD and PhD student Sune Nygård, Department of Veterinary Disease Biology, University of Copenhagen.

Re-use of existing breast cancer treatment
In the new study the researchers have shown that around 10 per cent of colorectal cancer patients harbor an aberration in the gene called TOP2A in their cancer cells. These tumors could potentially benefit from treatment with a specific chemotherapeutic drug - a so-called “anti-TOP2A treatment”, which is already used in breast cancer patients with this gene aberration.

Clinical study begins
Approximately 600,000 patients die of colorectal cancer each year worldwide.

“If the first treatment doesn’t cure a patient with colorectal cancer, the possibilities of additional treatment are limited,” says Nils Brünner, MD, professor at University of Copenhagen. “Therefore it is very important to find a new, efficient treatment,” he adds.

The research group from the Department of Veterinary Disease Biology and professor Per Pfeiffer at Odense University Hospital have received funds from The Danish Cancer Society to initiate a clinical trial.

Here it will be tested, if patients with the TOP2A gene defect could benefit from the targeted anti-TOP2A treatment.

“It is unique to go from a discovery in the laboratory towards a treatment for cancer patients at this pace. This is only possible when researchers and doctors work closely together,” says Nils Brünner, University of Copenhagen.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

EU Funding for Clinical Trials of a Placental Malaria Vaccine
PlacMalVac project has received an FP7 EU grant.
Tuesday, March 05, 2013
Scientific News
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!